Navigation Links
Breakthrough treatment reduces post-surgical scarring for glaucoma patients
Date:7/27/2012

Scientists at the Singapore Eye Research Institute (SERI) and Nanyang Technological University (NTU) have developed an innovative way to combat post-surgical scarring for glaucoma patients.

A clinical trial has shown that the use of a new drug delivery method has resulted in 40 per cent fewer injections needed by glaucoma patients to prevent scarring after surgery. This also means fewer hospital visits for these patients in future.

Glaucoma, a disease characterised by a build-up of pressure in the eye, is a major cause of blindness worldwide. It affects about 3 per cent of the population in Singapore and an estimated 30 per cent of sufferers require surgery to adequately control the disease.

However, success rates for glaucoma surgery in Asian patients are considerably lower than those reported in Caucasian patients because Asians have a higher risk of scarring after such surgery. Up to one in three operated patients requires a minor surgical procedure in the first six months in order to maintain the ideal low post-operative eye pressure.

"The post-operative scarring response is the major obstacle for successful glaucoma surgery. We've seen in our clinics that Asian patients scar earlier and more aggressively than their Caucasian counterparts, and a significant number require at least one post-operative intervention to treat this scarring response," said Associate Professor Tina Wong, Senior Consultant with SNEC's Glaucoma Service, and Head of the Ocular Therapeutics and Drug Delivery Research Group at SERI. She is also the senior author of this study.

The breakthrough treatment method is made possible by Professor Subbu Venkatraman, Acting Chair of NTU's School of Materials Science and Engineering, who invented a way to make the drug, which prevents post-surgical scarring, last longer at the site of the injection. This considerably increases the interval before the drug has to be administered again.

Using a gel known as hyaluronic acid, Prof Venkatraman discovered a way to contain the drug, 5-Fluorouracil (5-FU) inside the gel. "Leveraging NTU's expertise in controlled-release technology, we have found a way to deliver the drug 5-Fluorouracil gradually into the patient. This allows the drug to be time-released over several days, compared to the current effect of the drug which remains at the injected site for only a few hours. The benefit for patients who have undergone glaucoma surgery is clear fewer injections of the drug are needed. This results in less post-surgical scarring and fewer visits to the hospital."

The aim of glaucoma surgery is to create a new pathway for the aqueous fluid to flow out, thereby lowering eye pressure. During glaucoma surgery, a flap is created using the patient's own tissue to regulate the outflow of aqueous fluid. A small blister, known as a conjunctival bleb, marks the new surgically created filtration site.

The flap that allows fluid to flow out can be blocked if scar tissue forms, preventing the fluid from draining effectively and causing the eye pressure to rise again. This is a particularly common problem in Asian patients. To restore outflow through the surgical flap, the obstructing scar tissue needs to be removed by injecting 5-FU which prevents further scarring. This procedure is called bleb needling.*

The clinical trial involved 49 patients, who were randomised to receive an injection of either the current 5-FU solution or the new combined formulation following bleb needling. All subjects were followed up for three months. The trial was conducted at the Singapore National Eye Centre.

The team found that the subjects who were randomised to receive the new treatment had an improved post-operative outcome. "With this novel treatment, we observed a dramatically lower rate for repeat needling, with only 12 per cent requiring further intervention, whereas 50 per cent of subjects receiving the standard 5-FU solution treatment required further needling," said Dr Arun Kumar Narayanaswamy, Senior Clinical Research Fellow, SERI, and first author of this study.

"In addition, because these patients require fewer interventions, their risk of ocular infection and side effects are significantly reduced," he added.

Assoc Prof Wong, also an adjunct professor at NTU's School of Materials Science and Engineering, and Prof Venkatraman together with his team of scientists, are improving the new treatment method further using nano-encapsulation. The team aims to achieve a precise release of the correct amount of drug at a steady daily dose over a course of several weeks instead of just a few days as shown by the study.

"Because the acute and most active stage of wound healing occurs in the first twelve weeks after surgery, we ideally need a sustained time release of the anti-scarring drug that can be administered as a single injection and provide the right amount of drug to continually suppress the scarring response for that crucial time frame. That way, we won't have to keep injecting patients with top-ups, often on a fortnightly or even weekly basis which is not only inconvenient for the patient but greatly increases the risk of complications with each additional injection," said Assoc Prof Wong.

In the future, this novel treatment could also be applied at the time of the glaucoma surgery to further improve surgical outcomes, as well as reduce the possible need for or frequency of bleb needling interventions after surgery.

The study, published in the journal Ophthalmology early this year, has been shortlisted for a Best Clinical Research Oral Presentation Award at the second SingHealth Duke-NUS Scientific Congress, which will take place on 3 and 4 August at Raffles City Convention Centre.


'/>"/>
Contact: Nicole Lim
lim.nicole.natalie@singhealth.com.sg
65-655-74924
SingHealth
Source:Eurekalert

Related medicine news :

1. Breakthrough Brings Transparency to Male/Female Relationships
2. Trivedi Beef, LLC Announces Breakthrough Beef Industry Data without the use of Antibiotic Drugs, Hormones or Steroids
3. Ear, Nose & Throat Journal publishes research on breakthrough treatment for tonsil stones
4. An important breakthrough in immunology by IRCM researchers
5. Scientists make breakthrough in bile duct cancer with discovery of new gene mutations
6. Bascom Palmer Eye Institute announces breakthrough for degenerative vision disorder
7. Cedars-Sinai awarded $17.8 million grant to develop ALS treatment
8. Telephone therapy technique brings more Iraq and Afghanistan veterans into mental health treatment
9. New stroke treatments becoming a reality
10. Genome analysis of brain tumors showing the way to new treatment strategies
11. A new route for tackling treatment-resistant prostate cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... ... Agile Software Development, has been awarded a contract by the Center for Medicare ... (BPA) aims to accelerate the enterprise use of Agile methodologies in a consistent ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... for healthcare compliance program management, will showcase a range of technology and learning ... Assisted Living (NCAL) Convention and Expo to be held October 14–18, 2017 at ...
(Date:10/12/2017)... ... October 12, 2017 , ... The company has ... today’s consumer and regulatory authorities worldwide. From Children’s to Adults 50+, every formula ... the highest standard. , These products are also: Gluten Free, Non-GMO, Vegan, ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... AccentCare, a leader in post-acute health care, have expanded their existing home health ... Home Health. , AccentCare has been operating a joint venture home health company ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... HMP ... the recipient of a 2017 Folio Magazine Eddie Digital Award for ‘Best B-to-B Healthcare ... City on October 11, 2017. , The annual award competition recognizes editorial and design ...
Breaking Medicine News(10 mins):
(Date:10/10/2017)... Pa. , Oct. 10, 2017   West ... in innovative solutions for injectable drug administration, today shared ... West,s ID Adapter for improving the intradermal administration of ... Fourth Skin Vaccination Summit in May 2017 by Dr. ... Lead, Polio Department, World Health Organization (WHO), and recently ...
(Date:10/4/2017)... Oct. 4, 2017  South Korean-based healthcare product Development ... aide "cprCUBE" on Kickstarter. The device will educate the ... arrests with better efficiency compared to the dated and ... feedback on efficacy of the compression for a more ... a goal to raise $5,000. ...
(Date:10/2/2017)... Oct. 2, 2017 Diplomat Pharmacy, Inc. (NYSE: ... Software and Consulting, LLC , and named its founder ... based in Tennessee , will operate ... expands EnvoyHealth,s service offerings for health care partners to ... "In an interoperable world, technology ...
Breaking Medicine Technology: